TD 9544 (REG-112805-10) - Branded Prescription Drugs

ICR 201805-1545-020

OMB: 1545-2209

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2018-09-13
IC Document Collections
IC ID
Document
Title
Status
197381
Modified
ICR Details
1545-2209 201805-1545-020
Active 201505-1545-002
TREAS/IRS
TD 9544 (REG-112805-10) - Branded Prescription Drugs
Extension without change of a currently approved collection   No
Regular
Approved without change 02/27/2019
Retrieve Notice of Action (NOA) 10/30/2018
OMB understands that the IRS is currently in the process of revising the methodology it uses to estimate burden and costs. OMB expects that future ICRs under this OMB control number will include dollar estimates of annual burden costs to taxpayers calculated using this revised methodology.
  Inventory as of this Action Requested Previously Approved
02/28/2022 36 Months From Approved 02/28/2019
45 0 45
1,800 0 1,800
0 0 0

Section 9008 of the Patient Protection and Affordable Care Act (ACA), Public Law 111-148 (124 Stat. 119 (2010)), as amended by section 1404 of the Health Care and Education Reconciliation Act of 2010 (HCERA), Public Law 111-152 (124 Stat. 1029 (2010)) imposes an annual fee on manufacturers and importers of branded prescription drugs that have gross receipts of over $5 million from the sales of these drugs to certain government programs (covered entity/covered entities). The previously approved final regulations supersede temporary regulations and describe how the IRS will administer the branded prescription drug fee. Section 51.7T(b) of the temporary regulations provides that the IRS will send each covered entity notification of its preliminary fee calculation by May 15 of the fee year. If a covered entity chooses to dispute the IRS' preliminary fee calculation, the covered entity must follow the procedures for submitting an error report that are established in §51.8T.

PL: Pub.L. 111 - 148 9008 Name of Law: Affordable Care Act (ACA)
   PL: Pub.L. 111 - 152 1404 Name of Law: Health Care and Education Reconciliation Act of 2010 (HCERA)
   US Code: 26 USC 51 Name of Law: Branded Prescription Drug Fee
  
None

Not associated with rulemaking

  83 FR 14107 04/02/2018
83 FR 54653 10/30/2018
No

1
IC Title Form No. Form Name
TD 9544 (REG-112805-10) - Branded Prescription Drugs

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 45 45 0 0 0 0
Annual Time Burden (Hours) 1,800 1,800 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$0
No
    No
    No
Yes
No
No
Uncollected
Stephanie Bland 202 317-6855

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
10/30/2018


© 2024 OMB.report | Privacy Policy